Day One Biopharmaceuticals

IPO

Targeted Therapies for Children and Adults

Public · Brisbane, United States · Founded 2018 · $190.0M raised

Employees
51–200
Founded
2018
Business Model
B2B
Total Funding
$190.0M
Last Round
$130.0M Series BFeb 2021
Rounds
2
Type
Public

About

Day One Biopharmaceuticals is a commercial-stage oncology company focused on developing and commercializing targeted therapies for patients with cancer, beginning with pediatric cancers. The company's lead product, tovorafenib (OJEMDA), is the first FDA-approved therapy for pediatric low-grade glioma (pLGG) and is being explored in additional tumor types driven by BRAF alterations.

Summary

Day One Biopharmaceuticals is a Biotech company based in Brisbane, United States, founded in 2018. It has raised $190.0M in total across 2 rounds, most recently a $130.0M Series B round in Feb 2021. Investors include RA Capital Management, Canaan Partners and Fairmount Funds.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Secondary MarketSecondary MarketJan 2024
$175.0M

Sign up to see all 4 rounds

Series A through Secondary Market — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Day One Biopharmaceuticals on Indexed.vc
<a href="https://indexed.vc/companies/day-one-biopharmaceuticals"><img src="https://indexed.vc/api/badge/company/day-one-biopharmaceuticals" alt="Day One Biopharmaceuticals on Indexed.vc" width="260" height="76" /></a>